SAN DIEGO, May 28 /PRNewswire/ -- Entest BioMedical, Inc., a newly formed wholly-owned subsidiary of San Diego-based Bio-Matrix Scientific Group, Inc. (OTC Bulletin Board: BMSN) announced today the launch of its Web site (http://www.EntestBio.com) to focus on new stem cell research, including a proposed research to develop a new therapeutic solution for traumatic brain injury (TBI) using autologous adipose-derived (fat) stem cells representing a potential cure. There are currently 1.5 million new cases of TBI occurring in the U.S. each year, adding to the almost 6.5 million existing cases. The Company is also pursuing research in the use of fat stem cell therapy for spinal cord injury, in which approximately 200,000 patients in the U.S. suffer from this disability.
The site also highlights the Company's progress in developing a gestational diabetes screening test, as the exclusive licensee granted by
Along with background about types of stem cells and factoids, the new site also reviews Entest BioMedical's focus on the promising field of in vitro expansion of adult stem cells using other types of cells, such as peripheral stem cells and cord blood stem cells to treat cancer and other diseases. The R & D company is also exploring isolating hematopoietic stem cells from peripheral blood or bone marrow and differentiating them into immune cells, especially T cells.
"Our new Web site demonstrates Entest BioMedical's mission and key scientific personnel who are dedicated to discovering and developing new procedures, treatments and medical devices that improve the quality of life - leading research and technology that serve the present and help shape the future," said David Koos, Ph.D., DBA, Chairman and CEO.
About Entest BioMedical, Inc.
Entest BioMedical, Inc., a wholly-owned subsidiary of Bio-Matrix Scientific Group, Inc. (OTC BB: BMSN) formed in April 2009, focuses on research and development of traumatic brain injury (TBI) and spinal cord injury using autologous "adipose-derived" stem cells. Entest BioMedical is involved with R&D activities relating to stem cell therapies, diabetes testing and medical devices.
This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
|SOURCE Entest BioMedical, Inc.|
Copyright©2009 PR Newswire.
All rights reserved